Transglutaminase 1

Human keratinocyte transglutaminase


(TG1, recombinantly produced in E. coli)

Order
Quantity
Price
Status
150 µg 370 € available


Documents
Art. No. T009
Synonym TG1, TGase 1, keratinocyte protein-glutamine-γ-glutamyltransferase

keratinocyte transglutaminase TG1 T009 by Zedira
Molecular Weight 90 kDa
Source Recombinant, produced in E. coli
Purity > 90 % (visually by SDS-PAGE)
Activation Add 10 mM Ca2+ to activate His6-rhTG1.
Activity > 2,500 U/mg [Activity is determined by measuring the rate of fluorescence enhancement after His6-rhTG1-catalyzed monodansylcadaverine-incorporation into N,N-dimethylated casein according to Lorand et al., Anal. Biochem. 44 (221-231)].
1 U is defined as the increase in fluorescence intensity of 1 a.u./min (measured on a Cary eclipse fluorescence spectrophotometer, Varian; λex = 332 nm, λem = 500 nm; band filter = 5 nm; detector strength = 600 V; temperature = 37°C, assay volume = 1 ml)].
Appearance White lyophilized solid.
Description His6-rhTG1 is based on the TGM1-allele from I.M.A.G.E.-clone IRAKp961M1628 isolated from human skin squamous cell carcinoma. It is N-terminally fused to a hexahistidine-tag resulting in the encoded N-terminal amino acid sequence MHHHHHHMDGPR. His6-rhTG1 is purified by IMAC to more than 90 % purity.
Reagents The Transglutaminase is lyophilized from 50 mM Tris-HCl pH 8.0, 10 mM Glutathion
Reconstitution Add the volume of water specified in the certificate of analysis under aliquotation to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be cooled on ice for short term storage.
Application His6-rhTG1 catalyzes acyl transfer reactions from glutamin residues in proteins or peptides to primary amines, e. g. the formation of ε-(γ-glutamyl) lysine bonds between proteins by transferring the acyl group of a peptide-bound glutamine residue to the primary amino group of a peptide-bound lysine residue. His6-rhTG1 may also be used for immunoprecipitation.
Storage Store at ≤ - 20°C. Store working aliquots at ≤ - 20°C. Avoid repeated freezing and thawing.
Delivery at ambient temperature is possible
Reference(s) Chrobok et al., PLoS One. 2018, 13:e0196433
Plank et al., J Invest Dermatol. 2018, pii: S0022-202X(18)32817-3
Fischer et al., J. Invest. Dermatol. 2013, 133:1170-7
Fukui et al., FEBS J. 2013, 280:1420-9
Schaertl et al., J. Biomol. Screen. 2010, 15:478-87
Yamane et al., FEBS J. 2010, 277:3564-74
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA